Overview
- A majority of the FDA’s Pharmacy Compounding Advisory Committee voted to allow six of seven reviewed peptides to be used by compounding pharmacies, with close tallies reported over Thursday and Friday.
- FDA career scientists and public‑health experts advised against relisting because the peptides lack consistent identity, quality standards, and human safety and effectiveness data.
- Several panel members who backed the change have financial ties to peptide clinics and suppliers and were appointed or added after Health Secretary Robert F. Kennedy Jr. signaled support for broader access.
- If the FDA follows the advisory votes it must use notice‑and‑comment rulemaking before compounding can resume, a process that could take months and leave short‑term questions about enforcement and interim access.
- Broader compounding access could shrink the online gray market but also expand telehealth and clinic sales into a market analysts value at billions of dollars while leaving patients exposed to unproven therapies and safety risks.